[HTML][HTML] Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer
F Coppedè, A Lopomo, R Spisni… - World journal of …, 2014 - ncbi.nlm.nih.gov
Colorectal cancer (CRC) is one of the most common cancer worldwide and results from the
accumulation of mutations and epimutations in colonic mucosa cells ultimately leading to …
accumulation of mutations and epimutations in colonic mucosa cells ultimately leading to …
BRAFV600E Mutation and Its Association with Clinicopathological Features of Colorectal Cancer: A Systematic Review and Meta-Analysis
Background Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying
causative genetic mutations. The B-type Raf proto-oncogene (BRAF) plays an important role …
causative genetic mutations. The B-type Raf proto-oncogene (BRAF) plays an important role …
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
S Venderbosch, ID Nagtegaal, TS Maughan… - Clinical Cancer …, 2014 - AACR
Purpose: To determine the prevalence and prognostic value of mismatch repair (MMR)
status and its relation to BRAF mutation (BRAF MT) status in metastatic colorectal cancer …
status and its relation to BRAF mutation (BRAF MT) status in metastatic colorectal cancer …
[HTML][HTML] Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)
Background The microsatellite instability-high (MSI-H) phenotype, present in 15% of early
colorectal cancer (CRC), confers good prognosis. MSI-H metastatic CRC is rare and its …
colorectal cancer (CRC), confers good prognosis. MSI-H metastatic CRC is rare and its …
[HTML][HTML] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
Abstract Background BRAF V600E mutation plays a negative prognostic role in metastatic
colorectal cancer (mCRC), leading to a median Progression Free Survival (PFS) of 4–6 …
colorectal cancer (mCRC), leading to a median Progression Free Survival (PFS) of 4–6 …
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer
BACKGROUND BRAF mutations occur in 5% to 11% of patients with metastatic colorectal
cancer (mCRC) and have been associated with poor prognosis. The current study was …
cancer (mCRC) and have been associated with poor prognosis. The current study was …
KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases
NE Kemeny, JF Chou, M Capanu, AN Gewirtz… - Cancer, 2014 - Wiley Online Library
BACKGROUND The validity of the KRAS mutation as a predictor of recurrence‐free survival
(RFS) or overall survival (OS) is unclear. The current study investigated whether the …
(RFS) or overall survival (OS) is unclear. The current study investigated whether the …
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer
Background BRAF mutations occur in 5% to 10% of metastatic colorectal cancers and are
biomarkers associated with a poor prognosis. However, the outcomes with standard …
biomarkers associated with a poor prognosis. However, the outcomes with standard …
The impact of neural invasion severity in gastrointestinal malignancies: a clinicopathological study
F Liebl, IE Demir, K Mayer, T Schuster… - Annals of …, 2014 - journals.lww.com
Objectives: Because neural invasion (NI) is still inconsistently reported and not well
characterized within gastrointestinal malignancies (GIMs), our aim was to determine the …
characterized within gastrointestinal malignancies (GIMs), our aim was to determine the …
Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal …
D Baratti, S Kusamura, D Iusco, S Bonomi… - Diseases of the colon …, 2014 - journals.lww.com
BACKGROUND: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is
an effective but potentially morbid treatment for colorectal cancer peritoneal metastases. The …
an effective but potentially morbid treatment for colorectal cancer peritoneal metastases. The …